Therapeutic antibodies, vaccines and antibodyomes

mAbs

Volumn 2, Issue 3, 2010, Pages 347-356

  Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibodies; Antibodyome; Biologicals; Therapeutics; Vaccines

Indexed keywords

CATUMAXOMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PALIVIZUMAB; VASCULOTROPIN;

DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOGENICITY; IMMUNOPATHOLOGY; NONHUMAN; REVIEW; VACCINATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DESIGN; HUMANS; IMMUNE SYSTEM DISEASES; INFORMATION STORAGE AND RETRIEVAL; NEOPLASMS; VACCINES; ZEBRAFISH;

EID: 77953673590     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.3.11779     Document Type: Review

References (85)

1. Paul WE. Fundamental Immunology, Lippencott Williams & Wilkins, New York 2003.
2. Lombard M, Pastoret PP, Moulin AM. A brief history of vaccines and vaccination. Rev Sci Tech 2007; 26:29-48.
3. Dimitrov DS, Marks JD. Therapeutic antibodies: Current state and future trends-is a paradigm change coming soon? Meth Mol Biol 2009; 525:1-27.
4. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497
5. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228:1315-1317
6. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989; 341:544-546 (Pubitemid 19252529)
7. Huse WD, Sastry L, Iverson SA, Kang AS, ting-Mees M, Burton DR, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989; 246:1275-1281
8. Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991; 88:10134-10137 (Pubitemid 21915789)
9. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581-597
10. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5:147-159
11. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2:695-703. (Pubitemid 39200062)
12. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9:269-277
13. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-357
14. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373:1033-1040
15. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7:1001-1012
16. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9:423-430
17. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2:706-713
18. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 2007; 4:348.
19. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116:1167-1173
20. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31:459-467
21. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028 (Pubitemid 44343545)
22. Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008; 4:1537-1549
23. Dixit R, Coats S. Preclinical efficacy and safety models for mAbs: the challenge of developing effective model systems. IDrugs 2009; 12:103-108
24. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008; 13:725-732
25. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009; 8:223-235
26. De Groot AS, McMurry J, Moise L. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 2008; 8:620-626
27. Stas P, Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 2009; 12:169-173
28. Baker MP, Jones TD. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 2007; 10:219-227 (Pubitemid 46442221)
29. Onda M. Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 2009; 10:131-139
30. Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008; 14:191-202. (Pubitemid 351903454)
31. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 2003; 5:172-179
32. Emi AN, de Carvalho JF, rtur Almeida SC, Bonfa E. Immunogenicity of Anti-TNF-alpha Agents in Autoimmune Diseases. Clin Rev Allergy Immunol 2009.
33. Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 2006; 6:231-243 (Pubitemid 43290992)
34. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: Possible implications for immunogenicity. mAbs 2009; 1:332-338
35. Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-inf liximab. Pharmacogenet Genomics 2009; 19:383-387
36. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008; 36:755-768 (Pubitemid 351826873)
37. Mariani G, Fasolo A, De BE, Gianni L. Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 2009; 6:93-104.
38. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008; 8:157-165
39. Hall PS, Cameron DA. Current perspective-trastuzumab. Eur J Cancer 2009; 45:12-18
40. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-543
41. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008; 7:1152-1160
42. Sachdev JC, Jahanzeb M. Evolution of bevacizumabbased therapy in the management of breast cancer. Clin Breast Cancer 2008; 8:402-410
43. Patel DK. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008; 28:31-41.
44. Tassev DV, Cheung NK. Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 2009; 9:341-353
45. Jakobovits A. Monoclonal antibody therapy for prostate cancer. Handb Exp Pharmacol 2008; 237-256
46. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009; 13:339-362
47. Chen W, Zhu Z, Feng Y, Dimitrov DS. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent crossreactive HIV-1 neutralizers. Proc Natl Acad Sci USA 2008; 105:17121-17126
48. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460-470
49. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-234
50. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20:479-485
51. Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 2008; 17:1553-1558
52. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823-830
53. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105:20410-20415
54. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009; 4:34-41.
55. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 2003; 283:17-25. (Pubitemid 37501056)
56. Zhang MY, Choudhry V, Sidorov IA, Tenev V, Vu BK, Choudhary A, et al. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods 2006; 317:21-30. (Pubitemid 44822553)
57. Zhang MY, Dimitrov DS. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 2007; 13:203-212
58. Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun 2009; 387:387-392
59. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97:2426-2447
60. Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev 2006; 58:671-685
61. Zhou JX, Tressel T, Yang X, Seewoester T. Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J 2008; 3:1185-1200
62. Samaranayake H, Wirth T, Schenkwein D, Raty JK, Yla-Herttuala S. Challenges in monoclonal antibody-based therapies. Ann Med 2009; 41:322-331
63. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220
64. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broadspectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009; 16:265-273
65. DiMenna LJ, Ertl HC. Pandemic influenza vaccines. Curr Top Microbiol Immunol 2009; 333:291-321.
66. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246-251
67. Kubota-Koketsu R, Mizuta H, Oshita M, Ideno S, Yunoki M, Kuhara M, et al. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 2009; 387:180-185
68. Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barre syndrome. J Infect Dis 2008; 198:226-233 (Pubitemid 352019288)
69. Houot R, Levy R. Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev 2009; 23:137-142
70. Brown MJ. Therapeutic potential of vaccines in the management of hypertension. Drugs 2008; 68:2557-2560
71. Chen X, Chang CH, Goldenberg DM. Novel strategies for improved cancer vaccines. Expert Rev Vaccines 2009; 8:567-576
72. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009; 58:317-324
73. Dormitzer PR, Ulmer JB, Rappuoli R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol 2008; 26:659-667
74. Grunewald J, Tsao ML, Perera R, Dong L, Niessen F, Wen BG, et al. Immunochemical termination of self-tolerance. Proc Natl Acad Sci USA 2008; 105:11276-11280
75. Grunewald J, Hunt GS, Dong L, Niessen F, Wen BG, Tsao ML, et al. Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids. Proc Natl Acad Sci USA 2009; 106:4337-4342
76. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009; 390:404-409
77. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA 2007; 104:12123-12128 (Pubitemid 47185640)
78. Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, Choudhry V, et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 2006; 80:891-899 (Pubitemid 43062901)
79. Chen W, Zhu Z, Zhang M, Macagno A, Prabakaran P, Owens J, et al. All known cross reactive HIV-1 neutralizing antibodies are highly divergent from germline and their elicitation may require prolonged periods of time. AIDS Res Hum Retroviruses 2008; 24:11-12
80. Xiao X, Chen W, Feng Y, Dimitrov DS. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 2009; 1:802-817
81. Pederson T. The immunome. Mol Immunol 1999; 36:1127-1128
82. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640
83. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377 (Pubitemid 37075812)
84. Weinstein JA, Jiang N, White RA, III, Fisher DS, Quake SR. High-throughput sequencing of the zebrafish antibody repertoire. Science 2009; 324:807-810
85. Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci USA 2009; 106:20216-20221